Carcinogenic potency of alkylating agents in rodents and humans.

Alkylating agents are known to produce second tumors in cancer patients treated for their primary cancer. Since therapeutic doses are high and the pharmacokinetics of the drugs are thoroughly studied, these agents provide a unique opportunity to compare intrinsic carcinogenic potency between experimental animals and humans. We have examined the carcinogenicity of melphalan, chlorambucil, and cyclophosphamide in causing leukemia in patients treated for cancer or polycythemia vera and lymphosarcoma in rats and mice. A good correlation among species is observed when the carcinogenic potency is based on the total lifetime exposure to active species derived from these drugs.

[1]  Richard D. Thomas.  Drinking Water and Health , 1986 .

[2]  O. Raabe.  Dose-response analyses of bone cancers from radium. , 1981, Science.

[3]  T. A. Connors.  Alkylating agents. , 1990, Cancer chemotherapy and biological response modifiers.

[4]  M. Pike,et al.  A carcinogenic potency database of the standardized results of animal bioassays , 1984, Environmental health perspectives.

[5]  L. Ellwein,et al.  Cell proliferation in carcinogenesis. , 1990, Science.

[6]  J. Kaldor,et al.  Quantifying the carcinogenicity of antineoplastic drugs. , 1988, European journal of cancer & clinical oncology.

[7]  N. Sládek.  Metabolism of oxazaphosphorines. , 1988, Pharmacology & therapeutics.

[8]  B. Allen,et al.  Choice of dose measure for extrapolating carcinogenic risk from animals to humans: an empirical investigation of 23 chemicals. , 1989, Health physics.

[9]  Edmund A. C. Crouch,et al.  Interspecies comparison of carcinogenic potency , 1979 .

[10]  B. Chabner,et al.  Potential roles for preclinical pharmacology in phase I clinical trials. , 1986, Cancer treatment reports.

[11]  P. Morrison.  Effects of time-variant exposure on toxic substance response. , 1987, Environmental health perspectives.

[12]  N. Sládek,et al.  Half-life of oxazaphosphorines in biological fluids. , 1984, Drug metabolism and disposition: the biological fate of chemicals.

[13]  N. Sládek,et al.  Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. , 1984, Cancer treatment reports.

[14]  S. Eksborg,et al.  Oral melphalan pharmacokinetics — relation to dose in patients with multiple myeloma , 1989, Medical Oncology and Tumor Pharmacotherapy.